Maximizing patient adherence for optimal outcomes in psoriasis.
about
Using insights from behavioral economics and social psychology to help patients manage chronic diseasesTopical therapies for the treatment of plaque psoriasis: systematic review and network meta-analysesDevelopment of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP).Non-adherence to drug therapy and drug acquisition costs in a national population--a patient-based register study.Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis.Apprehension of the disease by patients suffering from psoriasisIdentifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study.Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12-17 years of ageEfficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.Treatment Satisfaction Among Patients with Moderate-to-severe PsoriasisAn Applicator Delivery System for Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Topical Suspension (Gel): Innovating Psoriasis Vulgaris Treatment Through Patient CollaborationProviding Guidance for Patients With Moderate-to-Severe Psoriasis Who Are Candidates for Biologic Therapy: Role of the Nurse Practitioner and Physician Assistant.Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study.Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.Use of clobetasol in lacquer for plaque psoriasis treatment.Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict.The Lived Experience of Psoriasis Patients from Social Stigma and Rejection: A Qualitative Study.Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long studyAdherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature.Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic diseaseAssessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ).Topical medication utilization and health resources consumption in adult patients affected by psoriasis: findings from the analysis of administrative databases of local health units.GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.Topical drug delivery systems in dermatology: a review of patient adherence issues.Does psychosocial stress play a role in the exacerbation of psoriasis?Non-adherence and measures to improve adherence in the topical treatment of psoriasis.Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary.Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature.Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology.Adherence in dermatology.Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile.The role of community pharmacists in supporting self-management in patients with psoriasis.Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp.Long-term management of scalp psoriasis: perspectives from the International Psoriasis Council.A novel formulation of mometasone furoate in psoriasis patients: a multicenter, randomized, double-blind clinical study.Patient preferences for psoriasis treatments: impact of treatment experience.Patient education about topical treatments.Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study.Moderate to severe psoriasis treatment challenges through the era of biological drugs.The efficacy of short-term clobetasol lotion in the treatment of scalp psoriasis.
P2860
Q27001544-73AD4103-E493-4182-B9F8-8E172641C4EBQ27003961-4C39F951-A133-4831-AB1B-C6CCD626C4EFQ34071609-54619EBA-0690-4A14-9252-70A4B7F86238Q34084953-A1745582-EA45-4FFE-8316-8EBF20343D2CQ34412891-3E3904F6-38ED-4DE0-A2D5-BC7DC9295EA0Q34457936-83FF2B94-4549-4EDC-B9D4-887EAC25DF75Q34497024-FDDEB5B7-8270-4FEF-A18F-64A81F50F7D5Q34982047-E04DFD45-0658-4C0E-B382-ADA84DE0C4ABQ35203542-0BBBC192-6F9F-4A35-8787-FE15F139FC78Q35686609-0B9FC406-00BB-45E5-8A5F-E29EA7B3F94CQ36360014-3BAAD7EA-7A07-46AC-8E39-B7BB0B514A76Q36628064-C8B4AB24-E7CC-4955-93B8-895F3AFFA32AQ36631474-0F58E3DD-9379-45E6-B852-B6C52B1FBD12Q36635181-0F93C057-0A62-4353-9BE5-7A8C4EB51F67Q36663256-A4510084-1313-4931-9B67-F03A5877BB22Q36999996-BE142C7D-E785-4027-A1BB-12AC128C183CQ37262823-2C49E009-D8BE-439A-96AB-0F94C251A8FCQ37309074-B8A357FD-6E50-4ADD-B7A2-E9380BA08F3CQ37427086-03918279-B09E-45A3-A135-91F2330A4A1EQ37505449-73AFDBBE-2F65-459C-88BD-698C01CC039EQ37638892-94FFC16D-AFFF-40F8-A789-5881A713F639Q37693752-A5C64066-CCF0-4E42-94A1-6DE3539F104EQ37695053-B69F39AC-3A9C-4870-9458-CAE39E0955F3Q38031916-D7587F11-C1EE-4ED5-A1D7-4252BA8DB264Q38116606-1EDB6ABD-3FE5-4A83-B821-8AD519B57E2EQ38200706-ABB5C88A-E61E-4E8C-A264-7349C0FC7B54Q38633601-17C36990-D77C-44CE-A2E3-270AA5B5B6CDQ38704121-122D5505-6A91-4101-861D-DCAEF2B0E69DQ38712213-018F06EC-3241-4050-B507-601E77E630D9Q38834869-C221DF1B-038A-47E8-8026-CE10C4686424Q39034449-7BB0D77C-AED8-4863-A835-147703DD3CC6Q40395123-A6ED9A49-E245-47D7-BD61-9ABB193DAF94Q44288342-73F26171-B512-4819-A224-9CB5709590B2Q44698309-9F564F90-5370-4CFE-9D67-602F41AF56C0Q44734250-873FEA70-3605-4DAD-91B2-2CFFF5099F3CQ44849386-18713742-DAC6-46FD-B6DE-BFB4D81AC61AQ44939341-CF6B8B96-13C9-4956-B2A4-FB89E607D975Q45636613-AFC8B2D9-C8C4-423E-BCAA-6B14188FE1D3Q46452013-1A7302F3-DE3A-4A14-AA71-F72DEF9EF29CQ48007058-DD03DBF4-6A91-4B79-B4BC-73638C569B75
P2860
Maximizing patient adherence for optimal outcomes in psoriasis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Maximizing patient adherence for optimal outcomes in psoriasis.
@en
Maximizing patient adherence for optimal outcomes in psoriasis.
@nl
type
label
Maximizing patient adherence for optimal outcomes in psoriasis.
@en
Maximizing patient adherence for optimal outcomes in psoriasis.
@nl
prefLabel
Maximizing patient adherence for optimal outcomes in psoriasis.
@en
Maximizing patient adherence for optimal outcomes in psoriasis.
@nl
P2860
P1476
Maximizing patient adherence for optimal outcomes in psoriasis.
@en
P2860
P356
10.1111/J.1468-3083.2011.04060.X
P478
25 Suppl 4
P577
2011-06-01T00:00:00Z